HIGHLIGHTED ARTICLES FROM ANNALS OF SURGICAL ONCOLOGY
Weekly Update
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
February 2. 2023
Hunt, K.K., Suman, V.J., Wingate, H.F. et al. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. Ann Surg Oncol (2023). https://doi.org/10.1245/s10434-022-12972-5
Synopsis: ACOSOG Z1031 (Alliance) was designed to determine which aromatase inhibitor is most effective for postmenopausal women with estrogen receptor–positive stage 2 to 3 breast cancer in the neoadjuvant setting. The local-regional recurrence rate of 509 women is reported here.
Improved Adherence to ATA Medullary Thyroid Cancer Treatment Guidelines
February 2, 2023
McMullin, J.L., Sharma, J., Gillespie, T. et al. Improved Adherence to ATA Medullary Thyroid Cancer Treatment Guidelines. Ann Surg Oncol (2022). https://doi.org/10.1245/s10434-022-12734-3
Synopsis: The 2009 ATA guidelines for medullary thyroid cancer were created to unify national practice patterns. Treatment was discordant from guidelines in 26% of cases after 2009 compared to 33% prior. Improved adherence to guidelines correlates with improved overall survival.
Listen to the ASO's new podcast, Speaking of SurgOnc®
Speaking of SurgOnc® is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).
The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals. Once a month, Dr. Greene will interview authors and leading experts in surgical oncology.
Listen to the podcast here.
ASO is the journal of choice of surgical oncologists and cancer multidisciplinary teams worldwide regarding surgical oncology research and education, and benefits surgeons, oncologists, hematologists, radiologists, general practitioners, pathologists, researchers, academicians, and other clinical professionals interested in all aspects of the surgical treatment of cancer. ASO strives to improve the practice environment in which high-quality surgical oncology care is delivered, to enhance the quality of life and survival of the surgical patient with cancer.
Join the conversation! Follow the journal on Twitter and Facebook. Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.
